Patient treatment
| Treatment protocol . | Patients (n = 38) . |
|---|---|
| HD9 (1994-1998) | |
| Arm A (4 × COPP/ABVD + RT-IF*) | 0 |
| Arm B (8 × BEACOPP baseline + RT-IF*) | 15 |
| Arm C (8 × BEACOPP escalated + RT-IF*) | 18 |
| Total | 33 |
| HD12 (1998-2002) | |
| Arm A (4 × BEACOPP escalated + 4 × BEACOPP escalated + RT-IF*) | 1 |
| Arm B (4 × BEACOPP escalated + 4 × BEACOPP escalated) | 2 |
| Arm C (4 × BEACOPP escalated + 4 × BEACOPP baseline + RT-IF*) | 1 |
| Arm D (4 × BEACOPP escalated + 4 × BEACOPP baseline) | 1 |
| Total | 5 |
| Treatment protocol . | Patients (n = 38) . |
|---|---|
| HD9 (1994-1998) | |
| Arm A (4 × COPP/ABVD + RT-IF*) | 0 |
| Arm B (8 × BEACOPP baseline + RT-IF*) | 15 |
| Arm C (8 × BEACOPP escalated + RT-IF*) | 18 |
| Total | 33 |
| HD12 (1998-2002) | |
| Arm A (4 × BEACOPP escalated + 4 × BEACOPP escalated + RT-IF*) | 1 |
| Arm B (4 × BEACOPP escalated + 4 × BEACOPP escalated) | 2 |
| Arm C (4 × BEACOPP escalated + 4 × BEACOPP baseline + RT-IF*) | 1 |
| Arm D (4 × BEACOPP escalated + 4 × BEACOPP baseline) | 1 |
| Total | 5 |
Data are numbers of patients. RT-IF indicates involved field radiotherapy; BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone; and COPP/ABVD, cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, vinblastine, dacarbazine.
RT-IF on bulk/residual mass.